Sofinnova Biovelocita II

Call for Ideas
Reserved to The Giovanni Armenise Harvard Foundation Scientists

March 2024
Strictly confidential
Who we are

50+ years of venture capital

€2.6b dedicated to life sciences

Europe focus – global reach

Funding entrepreneurs of game-changing companies

3 offices
Who we are

84 Professionals
21 Nationalities

Majority of Scientists
16 PhD, 5 MD, 41 MSc
100% Life Science focus

Healthcare & Sustainability

- Medical Devices
- Biopharma
- Food
- Agriculture
- Digital Medicine
- Enabling Technologies
- Chemicals
- Materials
A Unique Investment Platform Across the Life Science Value Chain
Sofinnova
Biovelocita II

Accelerating investment opportunities
Acceleration

To provide seed **funding**, **management** and our extensive **network** to startups
Sofinnova Biovelocita II Overview

Dedicated Team
Team of experienced entrepreneurs
6 professionals

Pan-European Fund

Scope
Biopharma
Early stage: Project, Seed

Proven Strategy
Lead investor
18 years of acceleration
Sofinnova Biovelocita II Team

Gabriella Camboni
Partner
M.D.,
Co-founder and COO of Novuspharma and EOS
Co-founder and CEO of BiovelocITA

Alex Leech
Partner
MBA
Co-founder and CEO of Alchemab
VP at SVHI London
CEO of Creabilis

Joel Yao
Partner
M.Sc., Ph.D
7 yr Principal, Sofinnova Capital

Matthieu Coutet
Partner
M.Sc.
15 yr in VC, AdBio Partners,
Inserm Transfer Initiative

Cristina Pelizon
Associate Program Manager
Ph.D.
7 yr Project Manager, BiovelocITA

Marie Duranteau
Project Manager
M.Sc., Ph.D.
5 yr at Sofinnova Partners

Highly qualified professional team
- strong scientific background
- pharma industry experience
- startups building, management and operations
Investment Stages

- **Project**
  - Collaborating with academia

- **Seed**
  - Creating new companies

- **Series A & follow-on**

**Acceleration**
Sofinnova Biovelocita II

Accelerating your Ideas

Strictly confidential
SBVII Process
From Projects to Acceleration

- **Triage**
  - Project Identification
    - Initial assessment of Investment proposal
    - SBVII Team

- **Project selection**
  - Evaluation
    - In-depth presentation and discussions with SBVII Team
    - Due diligence
    - Business planning
    - SBVII Team

- **Investment Decision**
  - Acceleration
    - Execution of business plan
    - SBVII Team Scientist/Founder engagement

**SBVII Process**
**From Projects to Acceleration**
SBVII Project Requirements

- Scope: development of therapeutics
- Innovation: MoA, design, product/platform
- Patentability – novel and inventive, the patent may not have been filed yet
- Technical feasibility
- Medical need
SBVII Assessment Criteria

1. **Science**
   - Scientific rationale, novelty, problem addressed, target, indication, product, potential advantages

2. **Execution**
   - Goal of the program, current status, activities, timelines, program deliverables, next steps

3. **Financials**
   - Investment required, use of proceeds
SBVII Selection Process

*Numbers of projects are hypothetical, for exemplification purposes
Proposal – Summary of Required Contents

- **Background Information**
  - Rationale, main ideas / assumptions
  - Landscape analysis, goals

- **Preliminary Data**
  - Scientific publications, unpublished data
  - Patents and IP rights (if any)

- **Applicability**
  - Overarching objective, market need, expected deliverables and impact

- **Advantages**
  - Potential market and major players and/or competitors
  - Potential advance vs. current therapies and interventions

- **Project Plan Summary**
  - Current status
  - Summary of the research plan
  - Investment needed
Business Plan

Detailed R&D plan
- Program deliverables and success criteria
  - In collaboration with the inventors
  - What/when (activities plan and timelines)
  - Who/where (collaborations, vendors, consultants)
- Budget/Financial plan
- Program milestones and go/no-go criteria
- IP strategy

Long-term strategy
- High-level development outline
- High-level financial planning

Armenise Scientist
**Sofinnova Biovelocita II Investment Scheme**

Seed investment of €200K-€500K

Research activities in Founder’s lab and outsourced

Program duration of 12-24 months

Execution of R&D Plan

Armenise Scientists
Sofinnova Biovelocita II – Beyond Step 3

Company stage

Further investment (e.g. €1-2M)

SBVII Team providing CEO and project management

Scientist is Founder

Seed

Armenise Scientist

Strictly confidential
This presentation (the “Presentation”) has been prepared by Sofinnova Partners (“Sofinnova”). The information contained in this Presentation is confidential and relates to the investment project named “Sofinnova Biovelocita II”. Unless otherwise stated herein, statements in this Presentation are made as of December 31st, 2023.

This Presentation has been prepared for the sole purpose of testing the interest of potential investors in a fund which is not yet established. It does not amount to an offer or placement to the potential investors to invest in the units or shares of that fund. The information contained herein is preliminary in nature, is not intended to be all-inclusive and is subject, in all respects, to further diligence and negotiation of the terms of the Sofinnova Biovelocita II project. The information set out herein is provided as of the date of the Presentation and Sofinnova is under no obligation to update, complete, revise, verify or amend the information contained in this Presentation and/or to provide any previous, current or future other materials in relation to Sofinnova or its products or services. This Presentation may not be relied on in any manner as legal, tax, investment, accounting or other advice or as an offer to participate in the Sofinnova Biovelocita II project.

A private offering of interests in the Sofinnova Biovelocita II investment vehicle will be made only pursuant to the Sofinnova Biovelocita II’s constituent documents, which will be furnished to qualified investors on a confidential basis at their request for their consideration in connection with such offering.

Confidentiality

This Presentation and all information contained herein are strictly confidential and for the exclusive use of their recipients. They shall not be distributed, published or reproduced, in full or in part, and the information contained herein must not be released by its recipients to third parties.

This Presentation and all information contained herein may not be supplied to the general public, as this Presentation is not a public offering of units or securities, nor used in connection with any offer for subscription or sale of units or securities to the public in any jurisdiction. No information provided in the Presentation constitutes or should be used or considered as an offer to sell or a solicitation of any offer to buy the units, securities or services of Sofinnova or any other issuer in any jurisdiction whatsoever.

The recipients of this Presentation undertake not to use the information received hereby for purposes other than those for which the information was communicated to them.

Sources

Some of the information contained in this Presentation has been obtained from published sources prepared by other parties and it has not been independently verified. Neither Sofinnova nor any other person assumes any responsibility for the accuracy or completeness of the information contained in this Presentation and no representation or warranty, expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of this information or opinions contained herein.

Performance and Track Record

The performance information presented for informational purposes only and is intended to emphasise the experience and historic investment activities of Sofinnova. Past performance is not indicative of future results and no assurance can be given that the investment objectives of the Sofinnova Biovelocita II project will be achieved or that investors will receive a return of their capital. The gross multiple represents the multiple of the investment before management fees, organizational expenses and the management company’s allocation of profit. Actual realized returns on unrealized investments will depend on, among other factors, future operating results, the value of the assets, market conditions at the time of disposition, any related transaction costs, and the timing and manner of sale, all of which may differ from the assumptions and circumstances on which the valuations used in the performance data contained herein are based. Accordingly, the actual realized returns may differ materially from the returns indicated herein.

Nothing contained herein should be deemed to be a prediction or projection of future performance of any investment.

Certain statements contained in this document may be estimates of future expectations and other forward-looking statements that are based on certain assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. No representation or warranty is made as to future performance or such forward-looking statements.

An investment in any strategy or fund managed by Sofinnova will involve significant risks, for a number of reasons, including the following risks which have been identified by Sofinnova as having potentially a material adverse effect regarding the potential investment of an investor in the project: risk of capital loss, risk associated with unquoted companies, currency risk, risks associated with evolving legal, tax and regulatory regimes, business and financial risks connected to venture capital investments, sectorial and geographical risks and risks associated with key people involved in the strategy’s management. Other risks which have not been identified yet may evolve or occur.

None of Sofinnova or any of its affiliates, advisors or representatives shall have any liability whatsoever for any loss howsoever arising from any use of this document or its content or otherwise arising in connection with this document.

United States of America

None of the interests of funds managed by the Sofinnova has been registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any U.S. state or other relevant jurisdiction. No such registration is contemplated. Neither the U.S. Securities and Exchange Commission nor any U.S. state or other authority or securities commission has reviewed or passed upon the accuracy or adequacy of this Presentation. Any representation to the contrary is a criminal offense.

This Presentation relates to investments managed by Sofinnova, which is not registered as investment advisers pursuant to the Investment Advisers Act of 1940, as amended. As a result, the protections of such registration shall not be afforded to any investor in any fund managed by Sofinnova.
Sofinnova Biovelocita II
For further information please contact

Cristina Pelizon
Associate, Program Manager
cpelizon@sofinnovapartners.com